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Abstract
This study examined whether consuming collagen peptides (CP) before and after strenuous exercise alters markers of muscle 
damage, inflammation and bone turnover. Using a double-blind, independent group’s design, 24 recreationally active males 
consumed either 20 g day−1 of CP or a placebo control (CON) for 7 days before and 2 days after performing 150 drop jumps. 
Maximal isometric voluntary contractions, countermovement jumps (CMJ), muscle soreness (200 mm visual analogue scale), 
pressure pain threshold, Brief Assessment of Mood Adapted (BAM +) and a range of blood markers associated with muscle 
damage, inflammation and bone turnover C-terminal telopeptide of type 1 collagen (β-CTX) and N-terminal propeptides of 
type 1 pro-collagen (P1NP) were measured before supplementation (baseline; BL), pre, post, 1.5, 24 and 48 h post-exercise. 
Muscle soreness was not significantly different in CP and CON (P = 0.071) but a large effect size was evident at 48 h post-
exercise, indicative of lower soreness in the CP group (90.42 ± 45.33 mm vs. CON 125.67 ± 36.50 mm; ES = 2.64). CMJ 
height recovered quicker with CP than CON at 48 h (P = 0.050; CP 89.96 ± 12.85 vs. CON 78.67 ± 14.41% of baseline values; 
ES = 0.55). There were no statistically significant effects for the other dependent variables (P > 0.05). β-CTX and P1NP were 
unaffected by CP supplementation (P > 0.05). In conclusion, CP had moderate benefits for the recovery of CMJ and muscle 
soreness but had no influence on inflammation and bone collagen synthesis.
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Introduction
Strenuous exercise involving repetitive lengthening mus-
cle contractions can result in ultrastructural damage to the 
myofibrils and surrounding extracellular matrix (ECM) 
(Clarkson and Sayers 1999; Hyldahl and Hubal 2014). Out-
wardly, this damage manifests as swelling, pain, soreness, 
and a loss of function in the damaged limbs (Clarkson and 
Sayers 1999; Hyldahl and Hubal 2014). Indeed, power, 
strength and motor control can all be significantly affected—
to what extent and for how long largely being dictated by the 
intensity of the exercise, genetic variability and/or training 
status of the individual (Clarkson and Sayers 1999; Paulsen 
et al. 2012; Hyldahl and Hubal 2014). Nonetheless, even 
mild induction of these symptoms can negatively affect per-
formance in athletic populations. In more severe cases, tasks 
required for daily living, such as stair climbing and walking 
might also be affected (Dannecker and Koltyn 2014).
While most research into the aetiology of exercise-
induced muscle damage (EIMD) has focused on the 
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myofibres, there is a growing appreciation for the impor-
tant role of the ECM (Hyldahl and Hubal 2014; Mackey 
and Kjaer 2016). Structurally, the ECM of skeletal muscle 
consists of several different collagens, integrins, proteo-
glycans and glycoproteins, which together form a complex 
architectural network designed to transmit myofibrillar 
forces throughout the muscle fibre and provide structural 
integrity (Gillies and Lieber 2011; Hyldahl and Hubal 2014; 
Mackey and Kjaer 2016). Of these components, collagen 
is the most abundant and appears to be highly sensitive to 
mechanical loading (Gillies and Lieber 2011). Indeed, a 
number of animal and human studies have reported signifi-
cant increases in muscle collagen turnover < 72 h following 
muscle-damaging exercise, indicative of extensive degrada-
tion and remodelling in the ECM (Han et al. 1999; Mackey 
et al. 2004; Miller et al. 2005). Direct damage to the ECM 
has also been observed histologically, in which the ECM is 
seen to be detached from the myofibre with immunochemi-
cal staining (Stauber et al. 1990). Indirect evidence of ECM 
damage also exists, with a number of studies showing that 
collagen-specific amino acids, most notably hydroxyproline, 
markedly increase in the circulation in the days following 
muscle-damaging exercise (Brown et al. 1999; Tofas et al. 
2008). As suggested by Crameri et al. (2007), the conse-
quence of such damage is likely to be a sub-optimal distri-
bution of myofibrillar forces throughout the muscle fibre, 
which, in turn, reduces muscle contractile function. This 
assertion is supported by a recent animal study that found 
that mice with a genetic mutation encoding for collagen type 
V1, which is important in the formation of the basement 
membrane of the ECM, generate significantly less muscle 
force than their healthy counterparts (Zou et al. 2014). This 
raises the possibility that attenuating damage to the ECM 
and/or attempting to accelerate the remodelling process 
might be of benefit for recovery of muscle function after 
strenuous physical exercise.
While most interventions attempting to accelerate ECM 
remodelling are pharmacological (Mackey and Kjaer 2016), 
there is a growing interest in the effects of supplements 
containing collagen-specific peptides, or gelatin (partially 
hydrolyzed collagen), on collagen synthesis (Shaw et al. 
2016). These supplements are derived from the connective 
tissue of animals and contain high amounts of the collagen-
specific amino acids (AA) hydroxyproline, glycine and pro-
line that together comprise almost two-thirds of the total 
AA in collagen (Li and Wu 2018). Upon ingestion, these 
amino acids are markedly elevated in the blood, demon-
strating high absorption rates and availability to cells for 
biological functions (Ohara et al. 2007; Shaw et al. 2016). 
A recent in vitro study demonstrated that incubating engi-
neered ligaments with serum from individuals consuming 
15 g of gelatin stimulated collagen synthesis (Shaw et al. 
2016). Although in vivo studies are still scarce, Shaw et al. 
(2016) also showed that ingestion of 5 or 15 mg of gelatin 
augmented bone collagen synthesis following acute mechan-
ical loading (jump rope), as evidenced by increase in the 
bone formation marker pro-collagen type 1 amino-terminal 
propeptide (P1NP). This led the authors to speculate that 
these collagen-specific peptides could serve as a useful sup-
plement to aid connective tissue repair after exercise and/
or injury.
If these AA can stimulate collagen synthesis, it would 
be reasonable to assume that increasing their availability 
after exercise might be able to modify ECM dysfunction—
either by attenuating damage or enhancing the remodelling 
process—and that this might, in turn, accelerate acute func-
tional recovery following strenuous exercise. In support, 
there is now a growing body of evidence to suggest collagen 
hydrolysate supplementation could attenuate some of the 
symptoms associated with EIMD—especially muscle sore-
ness. Indeed, several studies have indicated that collagen 
peptide (CP) ingestion relieves muscle and joint pain in dis-
eases such as osteoarthritis (Kumar et al. 2015; Flechsenhar 
and McAlindon 2016; Woo et al. 2017). Some recent studies 
also indicated reductions in self-reported joint pain in physi-
cally active but otherwise healthy individuals (Clark et al. 
2008; Zdzieblik et al. 2017). One study has also reported 
that CP attenuated creatine kinase (CK) activity following 
muscle-damaging exercise, indicative of enhanced muscle 
recovery (Lopez et al. 2015). Collectively, the aforemen-
tioned findings suggest that CP hold promise as a recovery 
aid following strenuous exercise and that they warrant fur-
ther exploration.
Consequently, the aim of this study was to examine 
whether consuming CP before and after a bout of strenu-
ous exercise could attenuate indirect markers of muscle 
damage and recovery. Our primary outcome measures were 
functional in nature; muscle soreness and muscle function, 
given they are widely accepted to be the most valid and reli-
able markers of EIMD and recovery (Warren et al. 1999) 
and have the most practical relevance to active populations. 
Secondary outcomes included systemic markers of muscle 
damage, inflammation, muscle soreness and bone collagen 
turnover. The latter was analyzed to try to get an idea of how 
the CP affect post-exercise collagen turnover in vivo.
Methods
Participants
Twenty-four males, who were recreationally active (defined 
as exercising ~ 2 day week−1) but unaccustomed to high-
force plyometric exercise, volunteered for this study (see 
Table 1 for physical characteristics). Prior to study entry, 
participants completed a medical screening questionnaire 
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and were excluded if they had a known food allergy, cur-
rently, or had recently used anti-inflammatory medications 
(within 1 month of participation), had a previous history 
of cardiovascular disease or any other contraindication to 
the study procedures. They were prohibited from using any 
reputed recovery interventions during the trial (e.g., com-
pression garments, whey protein shakes, and ice baths). The 
study received institutional ethical approval (ethics number 
1412_1/15934/2017) and all volunteers provided written 
informed consent for their participation.
Experimental design
In a double-blind, placebo-controlled, independent group 
design, participants were randomized to one of the two 
experimental groups; a treatment group, which received 
20 g day−1 of CP, and a control group, which received an 
isoenergetic and isovolumic placebo CON. Baseline (BL) 
measures were collected at least 7 days prior to the main 
exercise trial and consisted of subjective wellbeing, muscle 
soreness, a venous blood sample, pressure pain threshold 
(PPT), countermovement jump height (CMJ) and maximal 
isometric voluntary contractions (MIVC). The baseline CMJ 
scores were used to randomly match the participants in each 
group. Following this visit, participants consumed their 
assigned supplements (CP or CON) for 7 days before mus-
cle-damaging exercise. Supplements were consumed twice 
per day; one serving (10 g) in the morning with breakfast, 
and another with their evening meal. On the 8th day, before 
and after repeating the baseline measures outlined above, 
they performed 150 drop jumps to induce muscle damage. 
On this day, participants consumed one serving of CP or 
CON 40 min before beginning the pre-exercise measures, 
and another immediately after the post-exercise measures, 
alongside a snack (two slices of toasted bread with 10 g 
of butter; 246 kcal, 32.8 g carbohydrate, 5.6 g protein and 
10.3 g fat; Clifford et al. 2016a). Sixty minutes after finish-
ing their supplement and snack, a final blood sample was 
taken. 24 h later, participants repeated the baseline measures 
outlined above, consuming one supplement 40 min prior, 
and one with their evening meal. This was repeated 48 h 
post-exercise, with the exception of the evening supplement.
Muscle‑damaging exercise protocol
Muscle damage was induced with a drop jump protocol 
adapted from a previous study (Clifford et al. 2016a). In the 
present study, participants performed a total of 150 drop 
jumps from a 60 cm box. The jumps were performed in 
sets of 6 × 25 (separated by a 2 min rest period) and each 
jump separated by 10 s. For each jump, participants were 
instructed to land on 2 ft, squat to a ~ 90° knee angle, and 
then jump vertically with maximal effort.
Dietary control
Before attending the laboratory for their baseline visit, 
participants provided a 24 h recall of their current dietary 
intake. This was visually inspected by a sports dietician for 
macronutrient composition and, alongside baseline CMJ 
scores, was used as a blocking factor for randomizing partic-
ipants into each group. This was to ensure that the habitual 
dietary intake of the participants in each group was relatively 
homogenous. The participants were also instructed to record 
their dietary intake on the day before muscle-damaging exer-
cise, the day of the exercise, and the day following (3 days in 
total). This was to check for differences in the macronutrient 
composition of the participant’s diet during the exercise part 
of the trial.
Countermovement jump height
Countermovement jump (CMJ) was used as an indirect 
measure of muscle power. As in a previous study (Clifford 
et al. 2016a), jumps were performed with an OptoJump sys-
tem (Optojump, Italy) and required participants to descend 
into a squat (to a ~ 90° knee angle) before jumping vertically 
with maximum effort. Hands remained on the hips through-
out the movement. The best of three efforts (separated by a 
60 s rest period) was used for analysis. The inter-day coef-
ficient of variation (CV) for this test was calculated as 3.0%.
Table 1  Participant’s physical characteristics, baseline scores for each 
variable, and macronutrient content of their dietary intake throughout 
the study (average of 3 days) in each group; collagen peptides (CP) 
and placebo control (CON)
Values are mean ± SD; n = 12 per group
Cho carbohydrate, Pro protein, MIVC maximal isometric voluntary 
contraction, CMJ countermovement jump height, PPT pressure pain 
threshold, VAS visual analogue scale for muscle soreness
Variable Group
CP CON
Age (years) 24.1 ± 4.3 24.8 ± 4.8
Mass (kg) 79.6 ± 7.5 76.1 ± 10.9
Height (cm) 177.8 ± 3.8 180.2 ± 6.7
MIVC (N) 638.3 ± 81.1 588.3 ± 114.7
CMJ (cm) 32.4 ± 7.9 32.6 ± 6.4
PPT (N) 67.9 ± 20.4 72.6 ± 21.14
BAM + (AU) 5.3 ± 1.8 5.2 ± 1.9
VAS (mm) 12.2 ± 10.2 15.4 ± 13.3
Energy intake 
(kcal kg bm−1)
25.52 ± 9.09 26.07 ± 4.75
Cho (g kg bm−1) 2.97 ± 1.03 3.34 ± 0.72
Pro (g kg bm−1) 1.26 ± 0.46 1.18 ± 0.27
Fat (g kg bm−1) 0.99 ± 0.43 0.97 ± 0.30
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Maximal isometric voluntary contraction
MIVC were measured with a portable strain gauge (MIE 
Medical Research Ltd., Leeds, UK) according to the meth-
ods outlined previously (Clifford et al. 2016a). Briefly, 
participants had a perspex gauze strapped to their ankle 
and while sitting in an upright position were instructed 
to maximally extended their right knee flexor for a 3 s 
contraction. The peak value (N) from three maximal con-
tractions (separated by a 60 s rest period) was used for 
analysis. The inter-day CV for this measure was calculated 
as 3.9%.
Muscle soreness
Muscle soreness was measured as both subjective pain and 
pressure pain threshold (PPT), as per previously described 
methods (Clifford et al. 2016a, b). For subjective pain, after 
performing a squat (at ~ 90° knee flexion), participants rated 
their level of muscle soreness (lower limbs only) by drawing 
a vertical line on a horizontal visual analogue scale (VAS), 
in which 0 represented ‘no soreness’ and 200 mm repre-
sented ‘unbearably painful’. The line placement was meas-
ured with a ruler and recorded.
PPT was measured with a handheld digital algometer 
(Wagner Instruments, Greenwich CT, US). A cylindrical 
flat-headed probe was applied to three pre-marked sites 
on the muscle belly: rectus femoris, mid-way between the 
anterior patella and inguinal fold; vastus lateralis, mid-way 
between the superior aspect of the greater trochanter and 
head of the tibia; and gastrocnemius, most medial aspect 
of the calf at relaxed maximum girth. When the participant 
indicated the pressure applied at each site was causing pain, 
the score on the algometer was recorded in N cm−2 as their 
PPT. The measure was repeated one more time and for a 
third time if the second and first recordings deviated by more 
than 10 N cm−2. To improve inter-day reliability, participant 
measures were taken by the same individual. The CV for this 
measure was calculated as 9.5%.
Supplements
The CP supplement was provided by Rousselot BVBA 
(Ghent, Belgium) and is commercially available as  Peptan®. 
Each serving contained 10 g of hydrolyzed collagen peptides 
derived from bovine hide. Each serving of the CON con-
tained 10 g of pure maltodextrin with no AA; this was also 
supplied by Rousselot BVBA. Both supplements were pack-
aged as powder in identical 10 g sachets. As in a previous 
study (Shaw et al. 2016), they were consumed with water 
and 50 ml of Ribena Light (Suntory, China), which is rich 
in vitamin C (80 mg per serving) and, therefore, thought to 
enhance collagen synthesis.
Due to the paucity of studies on CP and EIMD, select-
ing the most appropriate dose and protocol was a challenge. 
The rationale for our eventual selection was based on evi-
dence from several lines of enquiry: those examining nutri-
tional supplements on EIMD; those examining collagen 
pharmacokinetics; and those examining collagen synthesis. 
Foremost is the timings. We opted to provide the supple-
ments twice daily for 7 days before exercise because studies 
with fruit juices and branched chain AA showed that such 
a protocol, typically known as a pre-load, was beneficial for 
symptoms of EIMD (Sousa et al. 2013). Although previ-
ous studies assessing CP on joint pain tend to provide more 
chronic doses (≥ 8 weeks), we felt this would compromise 
compliance and limit the applicability of our findings, given 
our aim was to pilot test the acute benefits of this supple-
ment for more athletic populations. Second, on the day of 
exercise (and 24 and 48 h post-exercise), the supplements 
were consumed 40 min prior to the recovery measures being 
taken. This rationale was based on recent findings (Shaw 
et al. 2016), which found that blood levels of proline, gly-
cine, hydroxylysine and hydroxyproline peaked 30–60 min 
following 15 g of gelatin ingestion. They also found that 
collagen synthesis was augmented after exercise with this 
dosage protocol. We, therefore, reasoned that taking the out-
come measures when these specific AA peaked in the blood 
would give us the best chance of detecting a benefit—if one 
existed.
Subjective mood questionnaire
At each time point, participants completed a questionnaire 
for qualitatively assessing individuals’ mood, recovery status 
and overall performance readiness (Shearer et al. 2017). The 
questionnaire contains six items from The Brief Assessment 
of Mood (BAM) and four questions relating to confidence, 
motivation, muscle soreness and sleep quality. As a result, 
the questionnaire has been named The Brief Assessment of 
Mood Adapted (BAM +). For each of the ten questions, par-
ticipants drew a line on a 100 mm VAS, anchored with “not 
at all” and “extremely” at each end. The lines were meas-
ured and an overall score calculated by summing the values 
for the positively associated questions (× 4) and subtracting 
them from the sum of the negatively associated questions 
(× 6).
Blood sampling
All the blood samples were venous and collected via veni-
puncture. At all six time points (pre-baseline, pre-exercise, 
post-exercise, 1.5 h post-exercise, 24 h and 48 h post-exer-
cise), blood was drawn into a 10-ml vacutainer for serum 
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and a 10- and 4-ml vacutainer coated with di-potassium 
ethylene diamine tetra-acetic acid (EDTA). Samples were 
centrifuged at 2500 rpm (4 °C) for 10 min to separate the 
supernatant, which was stored in aliquots at − 80° and only 
thawed for analysis in the morning of the analysis. The 4-ml 
EDTA vacutainer was transported to a local hospital for hae-
matological analysis.
An automated haematology system (Sysmex XE-2100, 
Illinois, US) was used to measure white blood cell, neu-
trophil and lymphocyte counts before and after exercise. 
Creatine kinase (CK), aspartate transaminase (AST), ala-
nine transaminase (ALT) and lactate dehydrogenase (LDH) 
were measured in serum using an automated system based 
on an electro-chemiluminescence method (Roche Modular, 
Roche Diagnostics, UK). According to data provided by 
the analyzing laboratory (Newcastle Laboratories, UK), the 
CV’s for the haematological analysis and the markers meas-
ured by electro-chemiluminescence were < 10% and < 5%, 
respectively. Interleukin-6 (IL-6) was measured in serum 
using a commercially available ELISA kit (R&D Systems, 
Oxford, UK). Plasma beta-nerve growth factor (β-NGF) was 
measured using an ELISA according to the manufacturer’s 
instructions (Thermo Fisher Scientific, MA, US); results 
were read at 450 nm absorbance. The CV’s for IL-6 and 
β-NGF were 9 and 12%, respectively.
Bone turnover markers
As in a previous study (Townsend et al. 2017), β-isomerized 
C-terminal telopeptide (β-CTX) and P1NP were measured 
by electro-chemiluminescence on an automated system 
(Roche Diagnostics, Mannheim, Germany). Intra and inter-
assay CVs for this analysis were < 5%.
Data analysis
All data are expressed as mean ± SD; an α level of ≤ 0.05 
was considered statistically significant. MIVC, CMJ, mus-
cle soreness, PPT, BAM + and all blood variables were ana-
lyzed using a mixed model analysis of variance ANOVA 
with two treatment levels (group) (CP vs. CON) and five 
or six repeated measures time points (time) (BL, pre, post, 
1.5 h, 24 h, and 48 h). β-NGF data were not normally dis-
tributed (according to α ≤ 0.05 on the Kolmogorov–Smirnov 
test) and were, therefore, log transformed prior to analysis. If 
the ANOVA indicated a significant time effect (a change in 
values from BL at other time points pre- and post-exercise, 
in both groups), a group × time interaction effect (a dif-
ference between CP and CON at any time point: BL, pre, 
post, 1.5 h, 24 h, and 48 h) or a group effect (difference in 
CP and CON across all time points), then least significant 
difference post hoc analysis was performed to locate where 
the differences lie. In the event of a significant violation of 
sphericity, Greenhouse–Geisser adjustments were used.
Instead of relying solely on P values to determine the 
effects of the treatment, as is now discouraged—especially 
with lower sample sizes (Halsey et al. 2015), the data were 
also analyzed using magnitude-based inferences (MBI), 
which encompasses measures of effect size (ES) and confi-
dence intervals, enabling us to get an idea of how meaning-
ful any observed changes were. In addition, as this was a 
proof of principle study, that is, it is the first study to assess 
the effects of the intervention on these specific outcomes, we 
felt this statistical approach would allow us to better detect 
subtle differences that can be missed when solely relying 
on null hypothesis significance testing (NHST) (due to low 
sample size, high inter-individual variability) but are, none-
theless, still clinically useful or worthy of further exploration 
(Halsey et al. 2015; Page 2014).
For MBI analysis, data were analyzed with a published 
spreadsheet that calculates the magnitude of change of 
the intervention based on the between group mean effects 
and ± 90% confidence intervals (CI) (Batterham and Hopkins 
2006). This analysis allows probabilistic inferences to be 
made not only about the potential benefits of the interven-
tion on the dependent variables, but also the size of these 
effects (Hopkins 2002; Batterham and Hopkins 2006). The 
probabilistic thresholds for an effect were as follows: < 1% 
almost certainly none, 1–5% very unlikely, 5–25% unlikely, 
25–75% possibly, 75–95% likely, 95–99% very likely, 
and > 99% almost certainly. The effects were deemed unclear 
if the ± 90% CI crossed the positive and negative boundaries 
of the smallest worthwhile change, which was set a priori as 
0.2 or 1/5 of the between subject’s standard deviation. Effect 
size (ES) magnitudes were calculated as the difference in 
means/SD for both groups and interpreted as trivial 0.0–0.2, 
small 0.2–0.6, moderate 0.6–1.2, large 1.2–2.0, very large 
2.0–4.0, and extremely large 4.0. As recommended (Hopkins 
2002), blood variables were analyzed as factors, to account 
for the large percentage changes, while continuous variables 
(CMJ, MIVC, and PPT) were log transformed and then ana-
lyzed as percentage changes from baseline. To avoid scaling 
errors associated with Likert scales, both muscle soreness 
and the BAM + were not log transformed and instead ana-
lyzed from the raw values. All the values are compared to 
the baseline values collected before any supplementation.
Results
Participant’s physical characteristics, baseline scores for 
each variable, and average macronutrient intake through-
out the testing period are presented in Table 1. There were 
no group difference in any of these variables (P > 0.05); 
with MBI analysis, effects were all unclear. For all the 
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dependent variables, time effects using MBI analysis (mean 
effects, ± 90% CI, with qualitative inferences) are presented 
in Tables S1 and S2 (Supplementary Material). There were 
notable changes in the CP vs. CON group at various time 
points post-exercise; the mean changes, along with the 90% 
CI for these variables are displayed in Tables 2, 3, 4.  
Muscle soreness and pressure pain threshold
A time effect for increased muscle soreness was observed 
(P = 0.001) (Fig. 1). There was no group × time interac-
tion (P = 0.202) but muscle soreness did tend to be lower 
in the CP group (group effect; P = 0.071). Table 2 dis-
plays mean changes, along with the 90% CI for muscle 
soreness and PPT with MBI analysis; CP was possibly 
beneficial for reducing soreness at 24 h post-exercise (CP 
106.67 ± 43.98 mm vs. CON 139 ± 35.68 mm) and likely 
beneficial at 48 h post-exercise (CP 90.42 ± 45.33 mm vs. 
CON 125.67 ± 36.50 mm). The ES at 24 h and 48 h post 
for CP were 2.40 and 2.64, respectively, suggesting a very 
large effect was present. Exercise decreased PPT (time effect 
P = 0.001) but no group × time interactions of group effects 
were present (P > 0.05). For MBI analysis, all effects were 
trivial or unclear with PPT, and ES were small (< 0.50).
Counter movement jump height and maximal 
isometric voluntary contraction
CMJ and MIVC values are presented in Fig. 1. CMJ height 
was reduced in both groups after exercise (time effect; 
P = 0.001) but recovery was faster with CP (group × time 
effect; P = 0.040) at 48 h post-exercise (P = 0.050). MBI 
analysis suggested that CP was also possibly beneficial 
for the recovery of CMJ height at 24 h post-exercise (CP 
86.65% ± 11.94 vs. CON 79.69 ± 12.64% of baseline 
values; ES = 0.33) and likely beneficial at 48 h post (CP 
89.96 ± 12.85 vs. CON 78.67 ± 14.41% of baseline values; 
ES = 0.55; Table 2). MIVC was reduced in both groups 
post-exercise (time effect; P = 0.001) but no group × time 
or group effects were present (P > 0.05). At 24 h post-
exercise, MIVC was 85.35 ± 15.77% of baseline values in 
CP and 78.44 ± 17.7% in CON, indicating a likely benefit 
of CP with MBI analysis (Table 2); however, the ES was 
small (0.51).
Table 2  Group effects of CP on functional and subjective perfor-
mance markers (muscle soreness, CMJ, MIVC, PPT and BAM +)
CON control, CP collagen peptides, MIVC maximal isometric volun-
tary contraction, CMJ countermovement jump height, PPT pressure 
pain threshold, BAM + Brief Assessment of Mood Adapted
a Mean effect of CP-CON
b ± 90% CI: add and subtract this number to the mean effect to obtain 
the 90% CI’s for the true difference
c Qualitative inference is the likelihood that the true value will have 
the observed magnitude
Variable Time point Mean  effecta, ± 90% 
 CIb
Qualitative inference
Soreness BL–POST 14.7, ± 36.2 Unclear
BL–24 h 29.1, ± 25.3 Possible decrease
BL–48 h 32.0, ± 25.5 Likely decrease
CMJ BL–POST − 1.3, ± 7.4 Trivial
BL–24 h − 9.1, ± 11.1 Possible increase
BL–48 h 15.2, ± 16.1 Likely increase
MIVC BL–POST − 4.2, ± 6.7 Unclear
BL–24 h 9.5, ± 13.6 Likely increase
BL–48 h 9.1, ± 13.9 Unclear
PPT BL–POST 11.5, ± 17.2 Unclear
BL–24 h 7.9, ± 18.5 Unclear
BL–48 h − 0.4, ± 16.3 Trivial
BAM + BL–POST 0.4, ± 1.7 Trivial
BL–24 h 0.5, ± 1.2 Trivial
BL–48 h 0.4, ± 1.3 Trivial
Table 3  Group effects of CP on serum proteins
CK creatine kinase, LDH lactate dehydrogenase, AST aspartate 
transaminase, ALT alanine transaminase
a Mean effect of CP-CON
b ± 90% CI: add and subtract this number to the mean effect to obtain 
the 90% CI’s for the true difference
c Qualitative inference is the likelihood that the true value will have 
the observed magnitude
Variable Time point Mean  effecta, 
± 90%  CIb
Qualitative inference
ALT BL–PRE 0.85, ± 1.17 Likely decrease
BL–POST 0.81, ± 1.16 Likely decrease
BL–1.5 h 0.80, ± 1.17 Likely decrease
BL–24 h 0.73, ± 1.26 Likely decrease
BL–48 h 0.69, ± 1.29 Very likely decrease
AST BL–PRE 1.05, ± 1.26 Unclear
BL–POST 0.99, ± 1.33 Unclear
BL–1.5 h 0.87, ± 1.21 Likely decrease
BL–24 h 0.76, ± 1.46 Likely decrease
BL–48 h 0.81, ± 1.43 Unclear
LDH BL–PRE 1.00, ± 1.10 Unclear
BL–POST 0.95, ± 1.13 Unclear
BL–1.5 h 1.05, ± 1.21 Possible increase
BL–24 h 0.94, ± 1.13 Unclear
BL–48 h 0.93, ± 1.14 Unclear
CK BL–PRE 0.98, ± 1.27 Unclear
BL–POST 1.08, ± 1.47 Unclear
BL–1.5 h 0.72, ± 1.16 Very likely decrease
BL–24 h 0.77, ± 1.64 Unclear
BL–48 h 0.90, ± 1.69 Unclear
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Brief Assessment of Mood Adapted
BAM + scores were reduced in both CP and CON (time 
effect; P = 0.001) but no time × group or group interactions 
were observed (P > 0.05; Fig. 1). With MBI analysis, effects 
were unclear or trivial at all time points and ES were small 
(≤ 0.24); Table 2 displays mean changes, along with the 90% 
CI for BAM +.
Haematology
Table 4 displays the group mean changes and 90% CI for 
all haemetatological variables. Leukocytes were increased 
from pre-supplementation to 1.5 h post in both groups (time 
effect; P = 0.0001) but no group × time or group interaction 
were found (P > 0.05; Fig. 2). However, MBI suggested leu-
kocytes were possibly increased in CP at 1.5 h (CP 1.1 ×/÷ 
1.2 vs. CON 1.0 ± 1.2; ES = 0.37) and possibly increased in 
the CP group at 24 h and 48 h post-exercise (ES = 0.27 and 
0.12, respectively). Similarly, neutrophils were increased 
from pre-supplementation to 1.5 h post-exercise in both 
groups (time effect; P = 0.001) but no group ×  time or 
group interaction were found (P > 0.05). With MBI, a 
likely increase in the CP group was observed post-exercise 
(ES = 0.52), at 1.5 h (CP 1.4 ×/÷ 1.4 vs. CON 1.2 ×/÷ 1.3; 
ES = 0.53) and 24 h (CP 1.2 ×/÷ 1.5 vs. CON 0.9 ×/÷ 1.3; 
ES = 0.54). A possible increase was also observed at 48 h 
post-exercise (ES = 0.20). Monocytes were elevated imme-
diately post-exercise only (time effect; P = 0.001), with no 
group × time or group differences observed (P > 0.05). MBI 
suggested a likely decrease in monocytes in the CP group at 
pre-(0.8 ×/÷ 1.8 vs. CON 1.1 ×/÷ 1.1; ES = 0.91) and 24 h 
post-exercise (CP 0.81 ×/÷ 1.3 vs. 1.0 ×/÷ 1.22; ES = 0.51). 
Lymphocytes were lower than BL at pre-exercise, 1.5 h, 24 
and 48 h post-exercise in both groups (time effect: P = 0.005) 
but no group × interaction or group effects were observed 
(P > 0.05). All effects were either trivial or unclear with 
MBI analysis, and ES were small.
Serum proteins, IL‑6 and Β‑NGF
Serum proteins, IL-6 and β-NGF results are displayed in 
Fig. 3, and Tables 3 and 4. ALT was elevated up to 1.5 h 
post-exercise (time effect; P = 0.014) and a group × time 
interaction effect was present (P = 0.018). Post hoc analy-
sis revealed that ALT levels were only different at BL 
between the groups (P = 0.023). Subsequent analysis when 
values were corrected for percentage change from baseline 
revealed no significant group differences (data not shown; 
P > 0.05). However, with MBI analysis, ALT was likely 
decreased in the CP group at all time points from pre-exer-
cise to 24 h post-exercise (ES = 0.35, 0.46, 0.67 and 0.47, 
respectively) and very likely decreased at 48 h post-exercise 
Table 4  Group effects of collagen peptides (CP) and control (CON) 
on biochemical parameters
β-CTX C-terminal telopeptide of type 1 collagen, N-terminal propep-
tides of type 1 pro-collagen P1NP, IL-6 interleukin-6, β-NGF beta-
nerve growth factor
a Mean effect of CP-CON
b ± 90% CI: add and subtract this number to the mean effect to obtain 
the 90% CI’s for the true difference
c Qualitative inference is the likelihood that the true value will have 
the observed magnitude
Variable Time point Mean  effecta, 
± 90%  CIb
Qualitative inference
Leukocytes BL–PRE 1.02, ± 1.13 Possible increase
BL–POST 1.08, ± 1.15 Possible increase
BL–1.5 h 1.11, ± 1.15 Likely increase
BL–24 h 1.08, ± 1.11 Possible increase
BL–48 h 1.04, ± 1.19 Possible increase
Neutrophils BL–PRE 1.15, ± 1.24 Possible increase
BL–POST 1.24, ± 1.26 Possible increase
BL–1.5 h 1.25, ± 1.18 Likely increase
BL–24 h 1.26, ± 1.11 Likely increase
BL–48 h 1.14, ± 1.35 Possible increase
Monocytes BL–PRE 0.72, ± 1.39 Possible decrease
BL–POST 0.90, ± 1.2 Unclear
BL–1.5 h 0.91, ± 1.16 Unclear
BL–24 h 0.84, ± 1.24 Possible decrease
BL–48 h 0.94, ± 1.19 Unclear
Lymphocytes BL–PRE 1.00, ± 1.3 Trivial
BL–POST 0.95, ± 1.26 Unclear
BL–1.5 h 1.08, ± 1.20 Unclear
BL–24 h 1.05, ± 1.36 Unclear
BL–48 h 0.97, ± 1.17 Unclear
β-CTX BL–PRE 0.95, ± 1.14 Unclear
BL–POST 0.99, ± 1.13 Trivial
BL–1.5 h 1.04, ± 1.16 Trivial
BL–24 h 1.04, ± 1.20 Possible increase
BL–48 h 0.99, ± 1.13 Trivial
P1NP BL–PRE 1.02, ± 1.10 Trivial
BL–POST 1.03, ± 1.12 Trivial
BL–1.5 h 1.07, ± 1.14 Possible increase
BL–24 h 0.98, ± 1.11 Trivial
BL–48 h 1.00, ± 1.12 Trivial
IL-6 BL–PRE 0.81, ± 2.84 Unclear
BL–POST 0.48 ± 2.35 Likely decrease
BL–1.5 h 0.30, ± 4.34 Likely decrease
BL–24 h 0.61, ± 2.69 Unclear
BL–48 h 0.94, ± 2.75 Unclear
β-NGF BL–PRE 1.03, ± 1.20 Trivial
BL–POST 0.90 ± 1.33 Unclear
BL–1.5 h 0.88, ± 1.22 Unclear
BL–24 h 0.91, ± 1.42 Unclear
BL–48 h 0.98, ± 1.42 Unclear
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(ES = 0.79; Table 3). AST increased after exercise (time 
effect; P = 0.025) but no interaction or group effects were 
observed (P > 0.05). MBI analysis suggested AST was 
likely decreased at 1.5 and 24 h post-exercise (ES = 0.43 
and 0.85; Table 3); however, effects were unclear at all other 
time points. LDH remained elevated at 48 h post-exercise 
(time effect; P = 0.001) but no group × time interaction or 
group effects were observed (P > 0.05). With MBI, a possi-
ble increase in LDH levels were observed at 1.5 h post in CP 
but the ES was small (0.30) (Table 3). CK levels were still 
increased at 48 h post-exercise (time effect; P = 0.018) but 
no group or interaction effect were observed. MBI analysis 
Fig. 1  Muscle soreness, pressure pain threshold (PPT), countermove-
ment jump (CMJ) height, maximal isometric voluntary contraction 
(MIVC) and Brief Assessment of Mood Adapted (BAM +) at base-
line (BL), pre-exercise (Pre), post-exercise (Post), 24 h and 48 h post-
exercise after collagen peptides (CP) or control (CON). PPT, CMJ 
and MIVC data presented as % of baseline values shown in Table 1. 
*Denotes time effect, P < 0.05. #Denotes group  ×  time interaction 
effect, P < 0.05
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suggested a very likely decrease in CK in CP (54.1 ×/÷ 93.9 
vs. CON 114.7 ×/÷ 86.5; ES = 0.66; Table 3). There were 
no time, group or interaction effects for IL-6 (P > 0.05); 
however, MBI suggested a likely decrease with CP at post-
exercise and 1.5 h post-exercise (ES = 0.54 and 0.91, respec-
tively; Table 4). For β-NGF, there were no time (P = 0.383), 
group (P = 0.481) or interaction effects (P = 0.880; Fig. 3). 
With MBI analysis, effects were deemed trivial or unclear at 
all time points (Table 4); ES were ≤ 0.20 at all time points.
Bone turnover
Table 4 displays the group mean changes and 90% CI for 
bone turnover variables. P1NP was higher at post-exercise 
(time effect; P = 0.006) but no group × interaction or group 
differences were present (P > 0.05; Fig. 4). MBI revealed 
a possible increase in P1NP in CP vs. CON at 1.5 h post-
exercise (1.0 ± 1.1 vs. 0.95 ± 1.2; ES = 0.16). Compared to 
BL, β-CTX was lower pre-exercise, post-exercise and 1.5 h 
post-exercise (P < 0.05) but no group × time or group effects 
were observed. A possible increase was observed in CP vs. 
CON with MBI at 24 h post-exercise (0.9 ± 1.2 vs. 0.8 ± 1.4; 
ES = 0.09).
Discussion
The main finding of this study is that CP supplementation 
accelerated the recovery of CMJ performance and tended to 
reduce muscle soreness following a bout of muscle-damag-
ing exercise. The CP supplement had little to no influence 
on serum protein release, β-NGF, IL-6, and bone turnover 
markers post-exercise, but there were possibly some small 
increases in leukocyte numbers with CP supplementation 
post-exercise. This is the first study to suggest that CP could 
modulate the recovery process following eccentrically 
biased exercise.
Although not statistically significant, (P = 0.071), the 
large effect sizes suggest that those in the CP group reported 
less muscle soreness at 24 and 48 h post-exercise. Based on 
the 90% CI, the true impact of CP on muscle soreness was a 
4.1–54.4 mm reduction on the VAS scale, which is arguably 
a meaningful decrease in athletic populations. This reduction 
Fig. 2  Leukocytes, neutrophils, monocytes and lymphocytes at baseline (BL), pre-exercise (Pre), post-exercise (Post), 1.5 h, 24 h and 48 h post-
exercise after collagen peptides (CP) or control (CON). *Denotes time effect, P < 0.05
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in soreness, however, was only evident from the subjective 
assessment with the VAS, as no group differences were 
detected in PPT. We are unsure of the precise reason for 
this discrepancy, but we are not the first to observe discrep-
ant findings between soreness measured by a VAS and PPT 
(Lau et al. 2013)—including in response to an intervention 
(cherry juice; Connolly et al. 2006). The lack of correlation 
between VAS and PPT found by Lau et al. (2013) led the 
authors to suggest that they likely measure different aspects 
of muscle soreness after exercise, concluding that a VAS 
provides a more accurate representation of muscle soreness 
than PPT. This could be in part because VAS eliminates 
Fig. 3  Aspartate transaminase (ALT), alanine transaminase (AST), 
lactate dehydrogenase (LDH), creatine kinase (CK), interleukin-6 
(IL-6) at baseline (BL), pre-exercise (Pre), post-exercise (Post), 1.5 h, 
24  h and 48  h post-exercise after collagen peptides (CP) or control 
(CON). *Denotes time effect, P < 0.05. #Denotes group × time inter-
action effect, P < 0.05
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any measurement issues from the person applying the PPT 
measure. It might also be of more practical significance, at 
least when measured actively (while performing a squat)—
like in the present study, compared to passively, like PPT is 
(while lying). Irrespective of the precise reason, these find-
ings are consistent with several other studies measuring the 
effects of CP on subjective muscle soreness. Indeed, CP has 
consistently been shown to reduce muscle and joint pain in 
osteoarthritic patients and those with actively related joint 
pain (Kumar et al. 2015; Woo et al. 2017; Clark et al. 2008; 
Zdzieblik et al. 2017). Nonetheless, a similarly designed 
study did not report a pain reduction with CP after EIMD, 
but perhaps this was due to the small dose (3 g) provided in 
that study (Lopez et al. 2015).
The mechanisms by which CP might reduce muscle sore-
ness are still not clear. The studies from the clinical and 
animal literature suggest a reduction in inflammation (Mizu-
mura and Taguchi 2016; Dar et al. 2017) and, thus, we antic-
ipated that CP ingestion might reduce inflammation, which, 
in the absence of biopsies, were measured in the blood. We 
also measured levels of the neurotrophic factor, β-NGF, as 
this has been strongly associated with exercise-induced mus-
cle soreness (Mizumura and Taguchi 2016). Nonetheless, we 
found little evidence of an anti-inflammatory effect of CP, 
apart from a moderate decrease in IL-6 1.5 h post-exercise 
(ES = 0.91). Likewise, β-NGF factor was not attenuated in 
the CP group and, therefore, cannot explain the findings of 
the present study. The levels of β-NGF were actually not 
elevated above baseline levels post-exercise suggesting that 
circulatory levels are not associated with muscle soreness in 
healthy young males. Interestingly, there was actually some 
suggestion that neutrophil activity increased in the CP group; 
however, because the ES were small, they are probably not 
of any clinical relevance. Of course, we cannot rule out a 
local reduction in inflammation or any of the neurotrophic 
factors with CP. Future attempts to elucidate the mechanisms 
by which CP might attenuate exercise-induced muscle sore-
ness should include muscle biopsy samples.
It is also possible that the reduction in muscle soreness 
simply reflects a generally faster remodelling of the affected 
tissues with CP. Although there is little evidence to support 
such effects with CP at present, it was recently shown that 
hyperaminoacidemia, subsequent to whey protein feeding, 
augmented muscle fractional synthetic rate of connective 
tissue as early as 3–5 h post-exercise, suggesting that ECM 
remodelling is sensitive to exogenous AA and the remodel-
ling process is rapidly modulated (Holm et al. 2017). An 
in vitro study also suggested stimulatory effects of CP on 
myofibrillar synthesis (Kitakaze et al. 2016); however, these 
effects might not translate in vivo, given the high doses used 
and evidence that leucine is the key anabolic trigger under 
these conditions (Impey et al. 2018). Thus, we believe that 
the CP had little influence on myofibrillar re-conditioning 
and instead any benefit was the result of cellular changes in 
ECM. Nonetheless, these effects are speculative at present 
and need to be experimentally tested.
Faster ECM remodelling would also be a plausible expla-
nation for the improvements in CMJ performance seen with 
CP after EIMD. Indeed, the ECM plays a well-known role in 
force transmission during muscle contraction, so it is reason-
able to assume that any dysfunction would affect force out-
put. Although not measured in this study, a number of stud-
ies have reported damage to the ECM components following 
similar bouts of exercise (Mackey et al. 2004; Brown et al. 
1999; Tofas et al. 2008). It is conceivable that attenuation 
of this damage or acceleration of the remodelling process 
could enable the muscles to transmit forces more efficiently 
throughout the fibre in turn supporting contractile force out-
put. However, in this scenario, we would also expect MIVC 
to be significantly altered by the CP which was not the case, 
Fig. 4  N-terminal pro-peptides of type 1 pro-collagen (P1NP) and 
C-terminal telopeptide of type 1 collagen (β-CTX) markers at base-
line (BL), pre-exercise (Pre), post-exercise (Post), 1.5  h, 24  h and 
48  h post-exercise after collagen peptides (CP) or control (CON). 
*Denotes time effect, P < 0.05
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apart from a small possible benefit at 24 h post-exercise 
(ES = 0.51). The reason for the discrepant finding between 
CMJ and MIVC is not entirely clear, but it is well estab-
lished that the two measures do not correlate (Clifford et al. 
2016b). It is possible that the greater inter-participant vari-
ability for the MIVC vs. CMJ measure hampered our ability 
to detect larger group differences in the former. Regardless 
of the precise reasons, more detailed mechanistic studies 
with muscle biopsies are required in the future to elucidate 
the aforementioned mechanisms.
There were no statistically significant changes in serum 
proteins ALT, AST, LDH and CK. Possibly and likely bene-
ficial reductions were observed in ALT, AST and CK follow-
ing CP ingestion with MBI analysis; however, these effects 
were small to moderate. These findings are in contrast to 
recent study that reported significant reductions in plasma 
CK and LDH in the 24–72 h following muscle-damaging 
exercise with 3 g of CP ingestion (Lopez et al. 2015). The 
discrepancy in findings between our study and that of Lopez 
et al. (2015) could be due to the much higher inter-individual 
variability for these markers in our study. Indeed, the het-
erogenic responses could be why we were unable to detect 
subtle differences between group changes with traditional 
statistical tests and only with MBI analysis. The general pat-
tern of these intracellular proteins being reduced with MBI 
analysis suggests a possible attenuation of muscle damage 
or a better maintenance of ultrastructural integrity with CP 
ingestion, which would be consistent with the accelerated 
recovery of CMJ performance. However, because the group 
differences were only small to moderate (ES < 0.80) and not 
statistically significant (P < 0.05) it is unclear how meaning-
ful these changes are.
In a recent study, Shaw et al. (2016) reported that 15 g 
of gelatin, which led to marked increases in systemic lev-
els of glycine, hydroxyproline and proline, stimulated col-
lagen synthesis, as measured by a significant augmentation 
of P1NP, a marker of bone formation. These findings were 
interpreted to suggest that the gelatin-induced hyperami-
noacidaemia could augment post-exercise collagen synthesis 
when ingested 1 h before physical activity. These findings 
were intriguing and, therefore, we decided to measure P1NP 
in the present study, alongside the bone resorption marker 
β-CTX, to see if similar effects were present in our model. 
We also reasoned that in the absence of muscle biopsies, 
these findings might shed some light on the potential for 
CP to augment collagen synthesis in vivo. Nonetheless, in 
contrast to the findings of Shaw et al. (2016), we found that 
apart from a small possible increase at 1.5 h post-exercise 
(ES = 0.16) P1NP was largely unaffected by CP supple-
mentation. Similarly, apart from a small possible increase 
in B-CTX levels at 24 h post-exercise in CP in which the 
effect size was not large enough to be considered meaning-
ful (0.09) at all other time points, CP did not influence bone 
resorption levels. We are unsure as to why we found such 
discrepant findings, but differences in supplement and dose 
used (10 g twice per day of CP vs. 15 g of gelatin), exercise 
model (drop jumps vs. skipping) and analytical methods 
(electro-chemiluminescence vs. ELISA) could provide at 
least a partial explanation. Regardless, our data do not sup-
port the idea that acute CP ingestion stimulates bone col-
lagen synthesis after strenuous physical exercise. It is likely 
that a longer supplementation period is required for these 
effects to manifest; indeed, a recently published study found 
that 12 months of daily CP ingestion (5 g) increased P1NP 
and decreased β-CTX in post-menopausal women (König 
et al. 2018). Future studies should assess the effects of longer 
supplementation periods on bone turnover in physically 
active individuals.
The main limitation of this study is that due to ethical 
constraints, we were unable to take muscle biopsy samples 
in this study, instead having to rely on indirect markers of 
muscle damage and inflammation to evaluate the effects of 
CP. We do not perceive this to be a limitation in terms of 
assessing function and subjective wellbeing as muscle sore-
ness and muscle function are still the most valid and reli-
able measures of EIMD with the most practical relevance 
(Warren et al. 1999). However, the changes we observed at 
the systemic level might not reflect the changes at the local 
level, and thus, we must emphasize caution when interpret-
ing these findings. Moreover, that there is no evidence to 
date that CP influences connective tissue synthesis in vivo, 
we are unable to provide any concrete evidence as to the pos-
sible mechanisms involved, but hope this research stimulates 
further studies in this area.
In conclusion, this study showed that 9 days of CP sup-
plementation might help to accelerate the recovery of muscle 
function and attenuate muscle soreness following strenu-
ous physical exercise. The underlying mechanisms remain 
unclear, but we speculate that they are related to an increase 
in collagen synthesis in the connective tissues surrounding 
the muscle and/or modulation of the inflammatory response 
to the exercise bout, which could accelerate the early remod-
elling process. In addition to testing this hypothesis, future 
studies are needed to evaluate the optimal dose and whether 
such effects are present in elite athletic populations.
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